- Fee assured
- Verified this account
- Urological malignancy
Mr Rochester qualified from Trinity College, Cambridge in 1998 with first class honours in medical sciences. After surgical training in Oxford he undertook a period of full-time laboratory research in urological oncology at the Institute of Molecular Medicine in Oxford which led to the award of an MD degree and election to the post of Royal College of Surgeons of England Hunterian Professor in 2006. His specialist urology training took place in the Eastern Deanery, predominantly in Norwich and Cambridge. Mr Rochester has subspecialty training in urological cancer surgery, particularly for the kidney and bladder and offers robotic and laparoscopic surgery for these conditions - cystectomy, radical and partial nephrectomy. He also has extensive expertise in Holmium laser enucleation for the prostate (HoLEP/laser prostatectomy, >700 cases) for benign prostate enlargement and the Urolift procedure. He has taught these techniques to many surgeons locally and across Eupope. He is currently the clinical lead for Urology at Norfolk and Norwich University Hospital.
Areas of interest
Laser prostatectomy (HoLEP); Urolift; Bladder cancer; Benign prostatic hyperplasia (BPH); Kidney (renal) cancer; Prostate disease including prostate cancer; Urological oncology; Laparoscopic procedures ('keyhole surgery'); Robotic surgery, Haematuria; Urinary tract disorders
Current NHS consultant posts held
Consultant Urological Surgeon & Clinical Director
Norfolk and Norwich University Hospital
Kidney, prostate and bladder cancer
Preoperative exercise interventions, CPEX testing
Mr Rochester is married with three daughters
Regional Innovation Award 2010
Royal College of Surgeons Hunterian Professorship 2006
NICE Shared Learning Awards Commendation 2017
HSJ awards 2018
Mutation detection in formalin-fixed prostate cancer biopsies taken at the time of diagnosis using next-generation DNA sequencing. Manson-Bahr D, Ball R, Gundem G, Sethia K, Mills R, Rochester M, et al J Clin Pathol. 2015 Mar;68(3):212-7
Prediction of complications after partial nephrectomy by RENAL nephrometry score.
Reddy UD, Pillai R, Parker RA, Weston J, Burgess NA, Ho ET, Mills RD, Rochester MA. Ann R Coll Surg Engl. 2014
Prevalence of ciprofloxacin-resistant Enterobacteriaceae in the intestinal flora of patients undergoing trans-rectal prostate biopsy in Norwich, UK.
Yazbek Hanna M, Tremlett C, Josan G, Eltom A, Mills R, Rochester M, Livermore DM. BJU Int. 2014 Jul 31.
Nephroureterectomy surgery in the United Kingdom in 2012: British Association of Urological Surgeons (BAUS) Registry data. Connolly SS, Rochester MA; B.A.U.S..BJU Int. 2014
Depletion of the type 1 IGF receptor delays repair of radiation-induced DNA double strand breaks. Turney BW, Kerr M, Chitnis MM, Lodhia K, Wang Y, Riedemann J, Rochester M, Protheroe AS, Brewster SF, Macaulay VM. Radiother Oncol. 2012 Jun;103(3):402-9.
Self Management Activation Randomised Trial for Prostatitis (SMART-P): study protocol for a randomised controlled trial. Rochester M et al. Trials. 2011
A prospective randomised trial of extended core prostate biopsy protocols utilizing 12 versus 15 cores. Rochester MA, et al J. Urol Int. 2009
Development and validation of risk score for predicting positive repeat prostate biopsy in patients with a previous negative biopsy in a UK population.
Rochester MA, et al BMC Urol. 2009
A randomised trial of conventional versus BAUS procedure-specific consent forms for transurethral resection of prostate.
Finch WJ, Rochester MA, Mills RD. Ann R Coll Surg Engl. 2009
Prospective evaluation of a novel one-stop testicular clinic.
Rochester M, et al Ann R Coll Surg Engl. 2008
The type 1 insulin-like growth factor receptor is over-expressed in bladder cancer.
Rochester MA, et al BJU Int. 2007
Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Patel NS, Dobbie MS, Rochester M, Steers G, Poulsom R, Le Monnier K, Cranston DW, Li JL, Harris AL.
Clin Cancer Res. 2006
A double-blind, randomized, controlled trial of topical glyceryl trinitrate for transrectal ultrasound guided prostate biopsy. Rochester MA, Le Monnier K, Brewster SF.
J Urol. 2005
HoLEP daycase rate 90%, readmission 4%
- BA Trinity College, Cambridge 1996
- MB BChir Cambridge University 1998
- MA Trinity College, Cambridge 2000
- MRCS (Eng) Royal College of Surgeons of England 2002
- MD Cambridge University 2005
- FRCS (Urol) Royal College of Surgeons of England 2008
Reference number 4583084
Details of entry to specialist register
- Urology, 2010
Affiliations / memberships
British Association of Urological Surgeons
Royal College of Surgeons of England
British Medical Association
- Spire Norwich Hospital Watton Road NORWICH...
- 18:00 - 21:00
- 01603 255574
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
In the event of an urgent query following treatment, Bupa members should use the following contact details
via switchboard 01603 286286